Endralazine

Endralazine
Clinical data
ATC code	C02DB03 (WHO) ;
Identifiers
	IUPAC name 6-benzoyl-3-hydrazinyl-5H,6H,7H,8H-pyrido[4,3-c]pyridazine;
CAS Number	39715-02-1 ;
PubChem CID	47608;
ChemSpider	43316 ;
UNII	L44741F05P;
KEGG	D08254 ;
ChEMBL	ChEMBL254193 ;
CompTox Dashboard (EPA)	DTXSID40192791 ;
Chemical and physical data
Formula	C14H15N5O
Molar mass	269.30 g/mol g·mol−1
3D model (JSmol)	Interactive image;
	SMILES c1ccc(cc1)C(=O)N2CCc3c(c/c(=N/N)/[nH]n3)C2;
	InChI InChI=1S/C14H15N5O/c15-16-13-8-11-9-19(7-6-12(11)17-18-13)14(20)10-4-2-1-3-5-10/h1-5,8H,6-7,9,15H2,(H,16,18) ; Key:ALAXZYHFVBSJKZ-UHFFFAOYSA-N ;
(what is this?) (verify)

Endralazine is an antihypertensive of the hydrazinophthalazine chemical class.[1] It is not approved for use in the United States.

References

Reid, J. L.; Kelman, A. W.; McSharry, D. R.; Elliott, H. L.; Meredith, P. A. (1983). "The pharmacokinetics of endralazine in essential hypertensives and in normotensive subjects". British Journal of Clinical Pharmacology. 16 (1): 27–32. doi:10.1111/j.1365-2125.1983.tb02139.x. ISSN 0306-5251. PMC 1427948. PMID 6882620. Retrieved 11 April 2019.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.